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ABSTRACT
The system of genetic control of innate immune responses to influenza infection and gene function allows for the 
development of systemic treatment of influenza with a focus on the phenotype of mutations based on individual 
genetic susceptibility to severe disease and/or the development of complications.
INTRODUCTION 
Analysis of the morbidity and mortality patterns of 
influenza in worldwide practice is based on studies of 
the age distribution and detection of risk groups [1-6]. 
At the same time, morbidity and mortality significantly 
depend on the distinctive genetic characteristics of 
individual populations and ethnic groups. On the one 
hand, the direct connection is established between a 
complicated course of influenza and haplotype HLA 
(Human Leukocyte Antigenes). On the other hand, the 
analysis of a number of gene polymorphisms, which 
determine the level of anti-viral defense, confirms 
that the contribution of single mutations and single-
nucleotide polymorphisms (SNP) to the morbidity and 
mortality from influenza is significantly higher than 
was previously considered [7-12]. Large scale studies on 
population genetics and sensitivity to influenza prove 
that the anti-epidemic actions in different regions of the 
country should be planned in accordance to the specific 
genetic characteristics of population.
It is also evident that in the process of anti-influenza 
vaccine development it is necessary to consider the 
possibility of the vaccine’s “genetic” orientation toward 
large population groups, as well as little to no reaction 
in response to vaccination in individuals with certain 
haplotypes of HLA [11,12]. Based on the results of genetic 
polymorphism analysis it is possible to conclude that in 
influenza therapy - in the case of mass morbidity, which 
is distinctive to pandemics - it is necessary to consider 
the possibility of a complicated course of disease caused 
by a defect in a certain part of the immune system and/or 
anti-viral defense. The understanding of genetic basics 
of pathology of infectious diseases, including influenza, 
could considerably change the vaccination practice as 
well as the basics of therapy itself. To that end, it is 
necessary to systematize the available information on 
genomes and the corresponding markers, distinctive 
for the cases with inadequate or pathological reaction 
to influenza and other accompanying infections. The 
SNP of the genes, listed and characterized below, is 
connected with the enhancement of human sensitivity 
to influenza or complicated course of this disease 
[9,13,14]. 
The role of interferon-induced transmembrane 
protein 3 (IFITM3) gene polymorphism in infectious 
pathology
Gene (IFITM3). One of the significant discoveries made 
during the years, passed after the last pandemic, was the 
detection of polymorphism in gene IFITM3 in groups 
of patients who developed a severe course of disease, 
caused by influenza virus A(H1N1)pdm09, with fatal 
complications in a number of cases (Fig.1) [9, 13-21]. 
Gene IFITM3 belongs to the family of genes that are 
induced by type I interferons (IFN). The IFITM3 protein is 
a transmembrane protein containing two transmembrane 
domains. Its functional activity is connected with human 
resistance to the strains of A(H1N1)pdm09 virus and 
many other infections, including Dengue and West Nile 
hemorrhagic fevers [13]. The protein IFITM3 exists in 
different isoforms; one of the most prevalent isoforms 
lacks the N-terminus domain (Fig.2) [18-21]. Analysis of 
this phenomenon led to the identification of a splicing 
site mutation that determines the enhanced human 
sensitivity to pandemic influenza [19, 20]. 
The analysis of the protein IFITM3 mechanism 
of action showed that it blocks the cells infection by 
preventing the entry of viral particles via endocytosis. 
[22]. This protein was shown to suppress the infection 
of Ebola, HIV-1 (human immunodeficiency virus type I), 
hepatitis C, and Dengue viruses [13]. It was also shown 
that IFITM3 protein suppresses the S-protein dependent 
endocytosis of Middle East Respiratory Syndrome 
coronavirus (MERS-CoV) [23], preventing the virus 
genetic material from entering the cell.
 Volume 2     Number 1     2015 11 mir-journal.org 
The risk of severe influenza infection
The wide spectrum of IFITM3 protein antiviral 
activity is caused by the protein’s profound effect on the 
stability of complex ATPhase of vacuoles (v-ATPhase) 
and endosomes. The interaction of v-ATPhase with 
endosomes, which leads to the relocation of Clatrin and 
pH reduction, plays an important role in the endocytosis 
of viruses [24]. This process is extremely attractive as a 
drug discovery target because it plays a key role in the cell 
infection process. It was established that classical Clatrin 
and v-ATPhase inhibitors are effective viral reproduction 
inhibitors and belong to broad-spectrum class of 
medicines. It turned out that Arbidol also belongs to this 
group of inhibitors [25]. Thus, one more mechanism of 
Arbidol action was revealed, which could explain its wide 
spectrum antiviral activity. However, the interaction 
of protein IFITM3 with viruses on the Clatrin pathway 
Fig. 1. The structure of the IFITM3 gene, the main coding transcripts and the corresponding proteins. The mutation leading to the 
formation of the alternative splicing site in exone 1 is shown as a vertical red line (single-nucleotide polymorphism rs12252 T/C). Start-
codons are marked as black triangles, protein coding exones of IFITM3 gene are shown in blue, the 1-21 fragment of protein IFITM3 [26] 
is shown in green.
Fig.2. The scheme of IFTM3 protein.  
N-end sequence 1-MNHTVQTFFSPVNSGQPPNYE-21, which is absent in the shortened mutant protein, is shown in green.
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of virus particles internalization on the early infection 
phases could not be restricted to the mechanism of anti-
viral defense. 
Two different transcripts could be formed during 
the expression of the IFITM3 gene – the full transcript 
and the shortened transcript version, which encodes 
the protein sequence, lacking the N-end 21 amino acid 
fragment [21]. 
In general, the IFITM3 protein is a restriction factor 
for virus reproduction, acting by the formation of the 
cells resistance to the different types of viruses. However, 
the detailed mechanisms of anti-viral defense formation 
in cells remain unknown in spite of the protein IFITM3 
discovery. As it was shown in a number of publications 
[18-20], mice with silenced IFITM3 gene had a more 
complicated course of influenza than mice with wild 
IFTIM3 gene. There is a known mutation of this gene in 
humans: substitution of Thymidine by Cytosine in the 
1st intron splicing site [18]. 
The connection of this mutation to the severity of 
influenza A(H1N1)pdm09 was studied in a European 
population group [19]. In this study, the frequency 
of hospitalizations was the criteria of complications 
during the development of infection. Patients who 
were hospitalized with severe influenza and/or the 
complications caused by influenza were found to have an 
enhanced frequency of homozygosity for a rare C allele of 
gene IFITM3. The frequency of SNP rs12252-C in patients 
with severe influenza totals 5.3% versus 0.3% (which is 
common) for the European population. Interestingly, the 
frequency of occurrence of SNP rs12252-C in Chinese 
populations was significantly higher. The genotype 
frequency CC reached approx. 25% in the Chinese 
populations. Among the patients in China who had 
severe forms of influenza the occurrence of genotype CC 
reached up to 69% (Fig.3).
The results on allelic frequencies of the IFITM3 
gene described here were obtained by the authors by 
the statistical data processing of 1,000 genomes [19]. 
The IFITM3 allelic frequency varied significantly in 
different populations. However, among members of the 
Han population, originating in the Southern province 
and inhabiting Eastern, Southern, and central China, 
the frequency of CC genotype rs12252 has been found to 
be as high as 69%. As a result of the detailed analysis of 
IFITM3 allelic frequency in the population and influenza 
morbidity (mortality), the authors come to the conclusion 
that the high frequency of occurrence of CC genotype 
contributes to the epidemiology of influenza in China. 
As a matter of fact, it is precisely in China that high 
frequencies of massive influenza breakouts are recorded 
that often lead to pandemics. 
The discovery of correlation between genotype IFITM3 
rs12252 and the clinical pattern of influenza infection 
prompted interest to study the separate components 
of “cytokine storm” in patients with the variant IFITM3 
gene [21]. These studies were conducted with patients 
infected with the pathogenic strain of A(H7N9) influenza 
virus that is currently in circulation. The patterns of 
expression of the following markers of “cytokine storm” 
were analyzed: MPC-1 (Monocyte Chemoattractant 
Protein-1), IL-1β (Interleukin-1β), IL-6, IL-8, IL-10, 
ТNF-α (Tumor Necrosis Factor), IFN-γ and C-reactive 
protein [27]. The authors studied the level of content 
of these proteins in peripheral blood. As a result of this 
study, it was established that the patients with genotype 
CC have more active synthesis and higher level of the 
secretion of protein MPC-1 in comparison with patients 
with CT or TT genotypes (Fig.3). The severity of disease 
also had direct correlation with these parameters  – 
genotype CC and excessive nonspecific immune 
response. Furthermore, the authors have conducted the 
study of cytokines (MIP-1α, MIP-1β, IL-1β, IL-6 and IL-8) 
in the lungs of dead patients. It turned out that the level 
of content of some pro-inflammatory cytokines in lungs 
was 100–1,000 times higher than in the peripheral blood. 
Thus, the development of “cytokine storm” is aided by 
IFITM3 rs12252 gene mutation.
To conclude the discussion of the role of gene 
IFITM3 polymorphism in infectious pathology it should 
be mentioned that the SNP rs12252 contributes to the 
development of Kawasaki syndrome – the early children’s 
vasculitis [15]. This abnormality is also common for certain 
population groups of South-East Asia and it could lead 
to a severe complication, such as aortic aneurysm [28]. It 
should be mentioned that influenza infection provokes 
vasculitis, including cerebral vasculitis, which suggests 
that the influenza infection affects the development of 
the pathology of the cardiovascular system.
Polymorphism of genes, which make an additional 
contribution to the severity of influenza infection
Gene polymorphisms have been studied in order to 
understand the susceptibility of populations to infectious 
diseases and their severe progression. These studies 
have fundamental significance for pediatric practice and 
global epidemic processes [9,14, 17]. The group of genes 
that have an impact on the development of complications 
over the course of influenza, is significantly widening 
over the years [9,17]. Table 1 presents a list of these 
genes and their probable role in the disruption of certain 
functions contributing to the eradication of influenza 
and other viral infections.
The lung surfactant proteins play an important role 
not only in providing the stability of oxygen transport 
but also in antibacterial and antiviral defense. Long-
term clinical observations showed that polymorphisms 
in genes that encode the surfactant proteins, and in 
particular the protein B (SP-B), play the key role in 
susceptibility to infections like influenza [29]. It was also 
established that the polymorphism of the SP-B gene is 
connected with a severe course of infection caused by the 
respiratory syncytial virus [30]. 
The role of complement system factors in bacterial 
and viral infections is very well known. In this respect, 
the role of the C1QBP gene polymorphism (Complement 
Component 1, Q subcomponent Binding Protein) in 
the complications of the course of influenza [8,33] is 
worth close attention. The gene C1QBP is encoding the 
protein C1QBP, which is a homotrimer in mature form. 
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Fig.3. The frequency of SNP rs12252 occurrence in the alleles of IFITM3 gene in different populations living in Asia and Europe.
A - the comparison of the genotypes in populations of China, Japan, Northern Europe and England;  
B - groups of patients: 1 - hospitalized patients, 2 - moderate severity influenza, 3 - severe course of influenza with complications; 
C - the frequency of alleles occurrence in patients with A(H1N1)pdm09 virus.
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The structural particularity of homotrimer C1QBP lies 
in asymmetric charge distribution on the surface of the 
molecule. This protein is interacting with a wide range 
of molecules involved in regulation of immune system: 
CDK13 [38], HRK [39], VTN [40], NFYB [41], FOXC1 [42], 
DDX21, DDX50, NCL [43], SRSF1, SRSF9 [44], CDKN2A 
[45] and other proteins including CD93 [46]. The function 
of C1QBP consists in antibody dependent cytolysis of 
infected cells with the involvement of complement and 
activation of phagocytosis. This protein is accumulated 
in mitochondrions during viral infection and inhibits 
signal transmission, which depends on RLR (RIG-I-like 
receptors), by interaction with the antiviral protein MAVS 
(Mitochondrial Anti-Viral signaling protein). The protein 
C1QBP is involved in the activation of blood coagulation 
cascade [47]. The action of C1QDP has pleiotropic 
character and depends on infection stage. 
CD55 (Complement Decay-Accelerating Factor; DAF) – 
acceleration factor for the complement decomposition – 
antigen of the Kromer system of blood types. DAF/CD55 
carries out anti-inflammatory functions by protecting 
cells from damage by a complement system as well as by 
the control of leucocytes migration to the inflammation 
center [47]. DAF/CD55 is expressed in vascular 
endothelium, mononuclears of peripheral blood and 
also in epithelial cells (including lung and endometrial 
epithelia) [48]. CD55 inhibits activation of C3 and C5 
components of complement system [49]. Significant 
level of expression of CD55 in respiratory epithelium 
stresses the importance of lungs protection from the 
damage caused as a result of excessive activation of the 
complement system. It is notable that the expression level 
of CD55 is regulated by progesterone and estrogen [50]. 
SNP in the gene’s CD55 (rs2564978 genotype T/T) 
promoter is associated with more severe course of influenza 
caused by A(H1N1)pdm09 virus [34]. As was established by 
experiments in vitro, the infection of cells by the influenza 
virus A(H1N1)pdm09 causes the intensification of the 
protein CD55 expression. Patients with T/T rs2564978 
genotype contain much less of CD55 on the surface of 
mononuclears of peripheral blood as compared with the 
patients with C/C and C/T genotypes [51]. 
The activation of the complement system makes a 
significant contribution to the lung tissue damage over 
the course of influenza infection. High levels of C3, C5b-
9 and MLB were detected in the lungs of mice infected 
with influenza A(H5N1) viruses, while the administration 
of C3aR antagonist significantly reduced the degree of 
inflammation in the lung tissue [52]. 
The mutation in the gene’s CD55 promoter, which 
apparently leads to the reduction of its expression, 
disrupts innate lungs defense mechanisms against 
the damage induced by complement during influenza 
infection leading to a higher chance of severe disease 
course and lethal outcome. 
Discussion of the correlation of human genes 
polymorphism with severity of influenza course brings 
up the problem of inadequate reaction of the innate 
immunity to infection. It is known that the activation of 
transcription of genes, encoding the proinflammatory 
cytokines, plays an important role in pathogenesis of 
severe influenza [21]. 
The system of genetic control of the innate immune 
response towards influenza infection as well as the 
functions of genes that are involved in downward 
regulation of the expression of genes, encoding the 
proinflammatory cytokines is of particular interest.  
Gene SOCS4 (Suppressor of Cytokine Signaling 4) 
holds one of the key positions in the hierarchy of genetic 
control of the activation of proinflammatory cytokines 
synthesis [36]. 
Table 1. Genes, whose mutations and polymorphism lead to complications during the course of influenza infection.
Gene Functions of the encoded protein Defect Reference
IFITM3 Factor of antiviral defense on the 
endosomes level




B – lungs surfactant
Pneumocytes defense, stability of teeth ridge, oxygen 
transport and clearance of viruses and bacteria
[29,30]
FCGR2A Fc-receptor – factor of infectious 
virus clearance
Defect of virus clearance [31,32]
C1QBP Factor of the complement system Defect of the complement system and complement 
dependent cytolysis of infected cells
[8,9,33]
DAF/CD55 Factor of the complement decom-
position acceleration, antigen of 
the Kromer blood group system 
Defect of the natural mechanisms of the lungs’ de-
fense from the damage caused by complement in the 
course of influenza infection
[34]
MBL2 Mannose-binding cell lectin Natural immunity regulation defect [35]
SOCS4 Suppressor of the cytokine depen-
dent signal systems
Defect of control of cytokine synthesis and activity 
(possible development of the “cytokine storm”)
[27,36]
SECISBP2 Complex of Se – dependent en-
zymes
Defect of the antioxidant system [37]
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The interest in the genetic control of these processes 
is natural. Recently, it was established that the genes 
of SOCS family play an important role in restraint 
of nonspecific natural immune response to different 
pathogens. Particularly, it primarily relates to the protein 
SOCS4 – the suppressor of cytokine signal systems 4. 
As a downward regulator of cytokine synthesis control, 
this protein belongs to the key factors of defense from 
excessive proinflammatory reaction to influenza virus. 
The proteins of this family control the innate and 
adaptive immune response by inhibiting the signaling 
pathway JAK/STAT [36].
SECISBP2 – gene, encoding the enzymatic complex 
(Sec Insertion Sequence Binding Protein 2), which in turn 
ensures the inclusion of selenocysteine in the protein 
structure [37]. Enzymes containing selenocysteine are 
the members of the cell’s Red-Ox defense system from 
oxygen radicals. Generation of oxygen radicals is the cells 
reaction to the majority of pathogenic microorganisms 
including viruses [37]. In the case of hereditary mutations 
in SECISBP2 gene, the acceleration of oxygen active forms 
synthesis leads to the systematic enhancement of cellular 
sensitivity to insulin. This is observed in mice with 
knocked out gene that encodes the antioxidant enzyme 
glutathione peroxidase 1, which contains selenium. 
The presence of gene SECISBP2 mutations in humans 
is clinically manifested by azoospermia, axial muscular 
dystrophy, disorder of T-lymphocytes proliferation 
and suppression of immune system in general. A high 
degree of lipid oxidation by peroxide and DNA oxidative 
damage, reduction of DNA damage reparation potential 
and shortening of telomeres are observed in individuals 
with these mutations. The pleiotropic effect of mutations 
in SECISBP2 gene is caused by the disruption of functions 
of the whole selenoproteome [37]. This hereditary defect 
should be especially prominent in the case of influenza 
infection and influenza-caused pneumonia. It is known 
that the influenza antioxidant therapy can provide 
significant clinical results in the area of intoxication 
syndrome relief and prevention of cardiovascular 
complications [52].
CONCLUSION
The understanding of genetic polymorphism in certain 
genes enables to direct the development of the systematic 
influenza therapy with the focus on phenotypic 
changes, caused by mutations, with consideration of the 
distribution degree of the hereditary susceptibility to 
severe course of influenza among groups of genetic risk 
and population, in general. 
In spite of the possibility of the wide distribution of 
mutations in the identified group of genes, related to the 
enhanced sensitivity to influenza, it should be recognized 
that the presentation level of the viral antigens within 
the certain population groups with the different types of 
HLA [10, 12] remains most important.
Mortality from influenza is registered in the acute 
period of the illness and usually on the peak of the 
epidemic, and then, as a “postponed mortality”, in the 
period from 1 to 3 months after the course of the disease. 
Most commonly, the lethal outcome is connected with 
the accompanying diseases, usually with cardiovascular 
pathology - namely heart attack and stroke. 
Thus, these factors should be taken in account while 
analyzing the genetic background of the population.
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